Weekly Clinical Updates

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans | Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study | FDA Authorizes Monoclonal Antibody for Treatment of COVID-19

Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology | SARS-CoV-2 direct cardiac damage through spike-mediated cardiomyocyte 3 fusion | Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised cancer patient.

An inflammatory cytokine signature predicts COVID-19 severity and survival | Moderna phase III clinical study protocol | Pfizer phase III clinical study protocol | Identifying Optimal COVID-19 Testing Strategies for Schools and Businesses: Balancing Testing Frequency, Individual Test Technology, and Cost

Smell and taste changes are early indicators of the COVID-19 pandemic and political decision effectiveness | Vascular Disease and Thrombosis in SARS-CoV-2- Infected Rhesus Macaques | COVID-19 and Excess All-Cause Mortality in the US and 18 Comparison Countries

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 | Rethinking Covid-19 Test Sensitivity — A Strategy for Containment | Adolescent with COVID-19 as the Source of an Outbreak at a 3-Week Family Gathering — Four States, June–July 2020 | Trends in COVID-19 Incidence After Implementation of Mitigation Measures — Arizona, January 22–August 7, 2020

Case-Control Study of Use of Personal Protective Measures and Risk for Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Thailand | Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 — COVID-NET, 13 States, March 1–August 22, 2020 | Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia